ReviewFrontiers in immunology2022
Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Human pegivirus 1 in healthy blood donors and in acute febrile patients from Mato Grosso, Midwestern Brazil.Archives of virology · 2026Observational
- Human Pegivirus Type 1 Prevalence in the General Population, Type 2 Diabetes and Cancer Patients in Taizhou, Jiangsu, China.Pathogens (Basel, Switzerland) · 2026Article
- Human pegivirus, Toscana virus and herpesviruses identified in cerebrospinal fluid from adults with unexplained neurologic disease, Spain, 2022-2023.The Journal of general virology · 2026Article
- A pegivirus associated with encephalitis in red-legged partridges shows neurotropism across avian species.Nature communications · 2026Article
- Characterization of near-complete humanMicrobiology resource announcements · 2026Article
- Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV.PLoS pathogens · 2026Article
- The future of transfusion and transplant microbiology safety: can new molecular technologies improve the safety of blood and transplant?BMC infectious diseases · 2026Review
- Molecular prevalence and genotypic distribution of human pegivirus-1 among Iranian hemodialysis patients.Virus research · 2025Article
- Identification of near full-length human pegivirus type 2 (HPgV-2) genomes in blood donor samples co-infected with hepatitis C virus (HCV).Microbiology resource announcements · 2025Article
- Frequency and Genotype Diversity of Human Pegiviruses (HPgV) in People Infected with Human Immunodeficiency Virus (HIV).Infectious diseases & clinical microbiology · 2025Article
- The genetic architecture of HIV-1 virulence.Virus evolution · 2025Article
- From viruses to cancer: exploring the role of the hepatitis C virus NS3 protein in carcinogenesis.Infectious agents and cancer · 2024Review
- Determinants of pegivirus persistence, cross-species infection, and adaptation in the laboratory mouse.PLoS pathogens · 2024Article
- The Blood Virome: A new frontier in biomedical science.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Review
- Human Immunodeficiency Virus-Human Pegivirus Coinfected Individuals Display Functional Mucosal-Associated Invariant T Cells and Follicular T Cells Irrespective of PD-1 Expression.Viral immunology · 2024Article
- Characterization of "Off-Target" Immune Modulation Induced by Live Attenuated Yellow Fever Vaccine.The Journal of infectious diseases · 2024Article
- Pegivirus Detection in Cerebrospinal Fluid from Patients with Central Nervous System Infections of Unknown Etiology in Brazil by Viral Metagenomics.Microorganisms · 2023Article
- Interplay between HIV and Human Pegivirus (HPgV) Load in Co-Infected Patients: Insights from Prevalence and Genotype Analysis.Viruses · 2023Article
- Genetic variability of human pegivirus type 1 (HPgV-1) among Congolese co-infected with hepatitis C virus in Brazzaville, Congo.IJID regions · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Two groups identified a novel human flavivirus in the mid-1990s. One group named the virus hepatitis G virus (HGV) and the other named it GB Virus type C (GBV-C). Sequence analyses found these two isolates to be the same virus, and subsequent studies found that the virus does not cause hepatitis despite sharing genome organization with hepatitis C virus. Although HGV/GBV-C infection is common and may cause persistent infection in humans, the virus does not appear to directly cause any other known disease state. Thus, the virus was renamed "human pegivirus 1" (HPgV-1) for "persistent G" virus. HPgV-1 is found primarily in lymphocytes and not hepatocytes, and several studies found HPgV-1 infection associated with prolonged survival in people living with HIV. Co-infection of human lymphocytes with HPgV-1 and HIV inhibits HIV replication. Although three viral proteins directly inhibit HIV replication
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.